CHMP
Market Access/ News/ News/ News/ Oncology
CHMP backs Roche’s lymphoma bispecific mosunetuzumab
Phil Taylor
CHMP, immuno-oncology, mosunetuzumab, non-Hodgkin lymphoma, Non-small cell lung cancer, Oncology, Roche, Tecentriq
0 Comment
Biogen pulls EU application for Alzheimer’s drug Aduhelm
Phil Taylor
Aduhelm, Alzheimer's disease, Biogen, CHMP, ema, EU, market access, neurology
0 Comment
EU regulator backs Idorsia’s Quviviq for adults with insomnia
Joy Persaud
CHMP, EU, Idorsia, insomnia, market access, MHRA, pharma
0 Comment
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
Phil Taylor
Aduhelm, Alzheimer's disease, Biogen, CHMP, Eisai, ema, neurology
0 Comment
CHMP minded to turn down Alzheimer’s drug Aduhelm, says Biogen
Phil Taylor
Aduhelm, Alzheimer's disease, Biogen, CHMP, Eisai, ema, EU, neurology
0 Comment
Novo Nordisk nears EU approval of obesity drug Wegovy
Phil Taylor
CHMP, Novo Nordisk, obesity, Saxenda, Wegovy
0 Comment
COVID antibodies from Roche, Celltrion backed for approval in EU
Phil Taylor
antibody, Celltrion, CHMP, coronavirus, COVID-19, Regeneron, Roche
0 Comment
EU backs broader use of Comirnaty as COVID booster than US
Phil Taylor
BioNTech, CHMP, Comirnaty, coronavirus, COVID-19, COVID-19 vaccine, ema, Pfizer
0 Comment